Rapport Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Rapport Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$125.10M	-$83.06M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$111.48M	-$78.31M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.86	$-3.78
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.86	$-3.78

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$52.65M	$56.80M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$512.43M	$314.93M
Everything the company owes — debt, unpaid bills, and other obligations.	$27.78M	$9.51M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$484.65M	$305.43M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$87.47M	-$64.83M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$616000	$2.40M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$88.09M	-$67.23M